Modulation of the "blood-tumor" barrier improves immunotherapy

Mitali Manzur, Juliana Hamzah, Ruth Ganss

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Blood vessels inside tumors are crucial for cancer survival and progression but equally contribute to the tumor's intrinsic resistance to therapy. Abnormal blood flow in the local tumor environment acts as a physiological barrier to the delivery of chemotherapeutic agents. Furthermore, tumor vasculature can also act as a barrier for immune cell migration into the tumor parenchyma. Much has been made of anti-angiogenic therapies that specifically inhibit vessel growth. However, recent findings demonstrate that the chaotic architecture of tumor blood vessels can be reversed which in turn normalizes blood flow and physical parameters in the tumor environment. Importantly, vessel normalization also improves lymphocyte migration into tumor tissue and immune destruction. Identification of regulator of G protein signaling 5 (RGS5) as a key modulator of the vascular barrier in tumor progression and regression has brought new insights into the molecular basis of vessel normalization and opens new therapeutic opportunities.
Original languageEnglish
Pages (from-to)2452-2455
JournalCell Cycle
Volume7
Issue number16
DOIs
Publication statusPublished - 2008

Fingerprint Dive into the research topics of 'Modulation of the "blood-tumor" barrier improves immunotherapy'. Together they form a unique fingerprint.

Cite this